Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$94.77 - $215.54 $142,155 - $323,310
-1,500 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$207.3 - $300.31 $310,950 - $450,465
1,500 New
1,500 $321,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.94B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Sabby Management, LLC Portfolio

Follow Sabby Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sabby Management, LLC with notifications on news.